Mai Capital Management Aim Immuno Tech Inc. Call Options Transaction History
Mai Capital Management
- $13 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AIM
# of Institutions
9Shares Held
811KCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY698KShares$1.84 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1KShares$2,6320.0% of portfolio
-
Cordasco Financial Network500Shares$1,3150.0% of portfolio
-
American Portfolios Advisors Holbrook, NY228Shares$5990.0% of portfolio
-
Jpmorgan Chase & CO New York, NY127Shares$3340.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $126M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...